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Abstract
 
Aims
 
To assess whether adding anthropometric measurements to an oral
glucose tolerance test (OGTT) can help to distinguish between transient and
persistent impaired glucose tolerance (IGT).
 
Methods
 
From the SLIM project (Study on Lifestyle-Intervention and IGT
Maastricht), a study designed to evaluate whether diet and physical activity
intervention can improve glucose tolerance in subjects at risk for diabetes, 108
subjects with IGT underwent a repeated OGTT 2—4 months after the initial
OGTT. Following the second test, subjects were classified as transient IGT, or
persistent IGT. Anthropometric measurements, including body mass index,
waist and hip circumference, sagittal and transverse abdominal diameters and
skinfold thickness measurements, were done during the second OGTT.
 
Results
 
Persistent IGT was diagnosed in 47 subjects (44%), transient IGT in
40 (37%), impaired fasting glucose in eight subjects (7%), and diabetes in 13
cases (12%). Two-hour blood glucose levels at the initial OGTT and subscapu-
lar skinfold thickness were significantly higher in subjects with persistent IGT
(2-h blood glucose 9.8 
 
–
 
 0.1 mmol/l vs. 10.2 
 
–
 
 0.1 mmol/l for transient IGT and
persistent IGT, respectively; subscapular skinfold thickness 25.4 
 
–
 
 1.4 mm vs.
29.8 
 
–
 
 1.2 mm for transient IGT and persistent IGT, respectively). After adjust-
ment for age, sex and family history of diabetes mellitus, logistic regression in-
dicated that 2-h blood glucose level during the initial OGTT represented the
strongest predictor of persistent IGT (
 
P
 
 < 0.02), followed by subscapular skin-
fold thickness (
 
P
 
 < 0.05). After adjustment for 2-h blood glucose levels during
the first OGTT, subscapular skinfold thickness remained significantly associated
with persistent IGT (odds ratio 1.84; 
 
P
 
 < 0.05).
 
Conclusions
 
In addition to the 2-h blood glucose level, subscapular skinfold
thickness was the best predictor of persistent IGT, suggesting that adding simple
anthropometric measures to oral glucose tolerance testing may improve the dis-
tinction between persistent and transient glucose intolerance.
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Introduction
 
Impaired glucose tolerance (IGT) is considered a precursor to Type
2 diabetes mellitus. Prevalence of IGT varies widely between
populations, from as low as 2.0% in rural populations to > 20%
in high-risk populations [1]. Cumulative incidence of diabetes
ranges from 23% up to 63% among subjects with IGT [2], and
is strongly dependent on baseline fasting and 2-h glucose con-
centration [3]. IGT is also associated with adverse cardiovas-
cular risk factors, and an increased risk of cardiovascular
disease [4,5]. Subjects with IGT benefit from (early) lifestyle
interventions, aimed at the prevention or delay of progression
to Type 2 diabetes mellitus and cardiovascular disease [6,7].
IGT is identified with an oral glucose tolerance test (OGTT),
but about 50% of the subjects revert to normal glucose toler-
ance at re-testing, indicating a poor reproducibility [8,9]. Sub-
jects with IGT on two occasions, known as persistent IGT,
have a higher risk of developing diabetes compared with those
returning to normal glucose tolerance at re-testing (transient
IGT) [10,11]. Subjects with persistent IGT also demonstrate
loss of the first-phase insulin response indicating early 
 
b
 
-cell
dysfunction, while subjects with transient IGT have a normal
insulin response [12]. It might be useful to distinguish persist-
ent and transient glucose intolerance on the basis of one single
glucose tolerance test. This would enable an intervention pro-
gramme to target those at the greatest risk of progression to
Type 2 diabetes mellitus.
A few studies have tried to identify additional factors
improving distinction between transient IGT and persistent
IGT [11,13,14]. The most important predictors were 2-h
blood glucose level, hyperinsulinaemia, and overall obesity
[i.e. body mass index (BMI)]. However, both total body fat
content and body fat distribution are important risk factors for
the development of Type 2 diabetes mellitus [15—17]. Simple
anthropometric measures (e.g. waist circumference, skinfold
thickness) could provide additional information to measures of
overall body fat content (i.e. BMI), and may have potential pre-
dictive value in distinguishing between persistent and transient
IGT. Indeed, it has been shown that concurrent use of simple
anthropometric assessments may provide a more complete
picture of risk of abnormal glucose and insulin regulation [18].
The purpose of the present study was to assess whether add-
ing single or multiple anthropometric measurements to oral
glucose tolerance testing improved the distinction between
transient and persistent IGT in middle-aged men and women.
BMI, waist and hip circumference, waist—hip ratio (WHR),
sagittal and transverse abdominal diameter and skinfold thick-
ness were used as anthropometric measures.
 
Patients and methods
 
Study design
 
The SLIM project (Study on Lifestyle-Intervention and IGT,
Maastricht) is a randomized controlled trial, designed to study
whether 3 years diet/physical activity intervention programme
can improve glucose tolerance and prevent Type 2 diabetes
mellitus (DM) in subjects with IGT. The study design is
described elsewhere [19]. In brief, subjects with an elevated
risk for the presence of disturbances in glucose tolerance (age
> 40 and/or a family history of diabetes), but no known DM,
were selected from an existing cohort, monitoring health and
disease in the Maastricht population, and invited to undergo
a first OGTT. Caucasian subjects with capillary 2-h glucose
levels > 7.8 mmol/l, in otherwise good health and willing to
participate in a lifestyle intervention programme, were invited
for a second OGTT (
 
n
 
 = 177). During the second OGTT the
physical examination included several anthropometric meas-
urements (see below). Final inclusion in the intervention study
was based on results of both OGTTs and several exclusion
criteria.
In this paper we describe 108 subjects with IGT at the first
OGTT, who underwent a second OGTT within 2—4 months
after the initial test. Those with impaired fasting glucose (IFG),
newly diagnosed Type 2 diabetes and high normal values at the
first OGTT were excluded from this analysis (
 
n
 
 = 69). In total,
results are described from 57 men (age 57.4 
 
–
 
 1.0 years, BMI
29.2 
 
–
 
 0.5 kg/m
 
2
 
) and 51 women (age 55.1 
 
– 
 
1.1 years, BMI
29.3 
 
–
 
 0.5 kg/m
 
2
 
). The Medical Ethical Review Committee of
Maastricht University approved the study protocol, and all
subjects gave their written informed consent before the start of
the study.
 
Glucose tolerance testing
 
Glucose tolerance was tested with a standard OGTT. After
an overnight fast (10—12 h), blood samples were drawn, after
which the subjects received the glucose load (75 g glucose, dis-
solved in 250 ml water; AVEBE, Veendam the Netherlands).
After 2 h another blood sample was drawn. During the initial
OGTT capillary blood was collected, and blood glucose level was
determined with a glucometer Elite (Bayer, Zurich, Switzerland).
Test strips are calibrated to give results equivalent to capillary
plasma; this means that IGT is defined as fasting < 7.0 mmol/l
and 2 h 
 
‡
 
 8.9 mmol/l, but < 12.2 mmol/l according to the
WHO [20]. During the second test, blood glucose levels were
determined in venous plasma with a standard enzymatic tech-
nique automated on the Cobas Fara centrifugal analyser at
340 nm (Roche Unikit III; Hoffman-La Roche, Basel, Switzer-
land). During the second OGTT a fasting blood sample was
drawn to determine the HbA
 
1c
 
 fraction by high-performance
liquid chromatography (reference value for our laboratory
4.4—6.2%).
It is known that glucose levels are higher in capillary blood
compared with venous blood or plasma. To validate this ap-
proach we measured the consistency in classification according
to the WHO criteria [20] between capillary blood and venous
plasma in a distinct group of subjects selected from the same co-
hort as the present study population. During standard OGTT
we simultaneously measured in 245 men and women (age
59.3 
 
–
 
 6.8 years, BMI 28.6 
 
–
 
 4.2 kg/m
 
2
 
) venous plasma and
capillary blood glucose concentration (with the methods de-
scribed above). Mean difference between capillary and venous
plasma glucose was 0.16 mmol/ l [95% confidence interval (CI)
0.02, 0.30] and 0.96 mmol/l (95% CI 0.68, 1.24) during fasting
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and at 2 h post OGTT, respectively. These differences closely
match the difference between (capillary and venous plasma) cut-
off values used for defining IGT according the WHO (fasting
0.0 mmol/ l and 2 h 1.1 mmol/ l). Consistency in classification
according to the WHO criteria between capillary blood and
venous plasma was good (69%, 
 
k
 
 0.55, 
 
P
 
 < 0.001 [21]).
 
Anthropometry
 
Body weight was measured with an electronic scale to the near-
est 0.1 kg, with the subject wearing only light clothing. Height
was measured with the subject standing on the floor without
shoes with the back straight against the wall to the nearest
0.5 cm. BMI was calculated as the ratio of the weight and
height squared (kg/m
 
2
 
). Skinfold thickness was measured twice
using a skinfold calliper at the triceps, biceps, subscapular and
suprailiacal region. The sum of peripheral skinfold (triceps and
biceps) and the sum of trunk skinfold (subscapular and suprail-
iacal) was computed. Waist circumference (waist) was measured
with the subject in the standing position at the level midway be-
tween the lowest rib and iliacal crest to the nearest 0.5 cm; hip
circumference was measured at the maximum circumference
over the buttocks to the nearest 0.5 cm. WHR was computed as
the ratio between waist and hip circumference. Sagittal and
transverse abdominal diameter were measured with the subject
in a recumbent position, at the level of the crista iliaca to the
nearest mm using a sliding beam calliper. The same person did
all the anthropometric measurements.
 
Classification of subjects
 
The results of the second OGTT were interpreted according to
the WHO criteria: IGT fasting < 7.0 mmol/l, 2 h 
 
‡
 
 7.8 and
< 11.1 mmol/l [20]. In the subsequent (statistical) analysis com-
parisons were made between subjects returning to normal glu-
cose tolerance at the second test (transient IGT) and subjects
remaining impaired glucose tolerant (persistent IGT).
 
Statistical analysis
 
Date are expressed as mean 
 
–
 
 
 
SEM
 
. All variables were checked
for normal distribution. Differences between groups were ana-
lysed with an unpaired 
 
t
 
-test. The predictive value of anthropo-
metric variables for having transient or persistent IGT was
analysed by means of logistic regression analysis. Dependent
(nominal) variable was persistent IGT or not. For each anthro-
pometric variable, logistic regression analysis was carried out
using sex, age, family history of diabetes and 2-h glucose at the
initial test as covariant. Odds ratios were expressed according
to a 1 
 
SD
 
 difference in the selected anthropometric variable.
Level of significance was set at 
 
P
 
 
 
£ 
 
0.05. All analyses were
performed with Statview 5.0 for Macintosh (SAS, Cary, NC, USA).
 
Results
 
In total 108 subjects, 57 men and 51 women, participated
in both OGTTs. Outcome of the second OGTT is depicted in
Table 1. Normal glucose tolerance at re-testing was found in
40 subjects (37%), IGT in 47 subjects (44%), impaired fasting
glucose in eight subjects (7%) and newly diagnosed Type 2
DM in 13 subjects (12%). When split by sex the number of
subjects returning to normal was not different between men
and women (see Table 1). Only the data from the 40 subjects
returning to normal glucose tolerance at re-testing (transient
IGT) and the 47 subjects remaining IGT (persistent IGT) were
used in the following analysis.
Average time between the initial OGTT and the second
OGTT was 79 
 
–
 
 47 days (mean 
 
–
 
 
 
SD
 
), and no differences in
average time between tests were observed between subjects
with transient and persistent glucose intolerance (data not
shown). Furthermore, no difference in change in body weight
between the first and the second OGTT was observed between
groups (data not shown).
Anthropometric variables and results of the initial OGTT
are depicted in Table 2 for transient IGT and persistent IGT.
Post load blood glucose concentrations during the initial
OGTT were higher in persistent IGT compared with transient
IGT (
 
P
 
 < 0.01). Fasting blood glucose concentrations during
the initial OGTT tended to be higher in persistent IGT com-
pared with transient IGT (
 
P
 
 = 0.09). Body weight, BMI and
age were not different between groups. No significant differ-
ences were found in waist circumference, WHR and sagittal
and transverse abdominal diameter between subjects with per-
sistent and transient IGT (see Table 2). Subscapular skinfold
thickness was higher in persistent IGT compared with tran-
sient IGT (25.4 
 
–
 
 1.4 mm vs. 29.8 
 
–
 
 1.2 mm for transient IGT
and persistent IGT, respectively; 
 
P
 
 < 0.02). The summations of
peripheral, truncal and all skinfold measurements were not
significant different between transient and persistent glucose-
intolerant subjects.
Logistic regression analysis revealed that the 2-h blood
glucose level at the initial test was the strongest predictor
of persistent IGT [odds ratio (OR) for 1 
 
SD
 
 difference 2.32;
 
P
 
 < 0.02]. To evaluate whether anthropometric measurements
were of (additional) predictive value in distinguishing between
transient and persistent IGT, logistic regression analysis was
performed after adjustment for age, sex, family history of DM,
and 2-h blood glucose level at the initial test (Table 3). Persist-
ent IGT was predicted by an increased subscapular skinfold
(OR for 1 
 
SD
 
 difference 1.84; 
 
P
 
 < 0.05). WHR (OR 1.73),
transverse abdominal diameter and sum of truncal skinfolds
were also associated with an increased risk of having persistent
Table 1 Results of the second oral glucose tolerance test
 
 
Men Women All
Normal glucose tolerance 19 21 40 (37%)
Impaired fasting glucose 6 2 8 (7%)
Impaired glucose tolerance 26 21 47 (44%)
Type 2 diabetes mellitus 6 7 13 (12%)
Total 57 51 108
Classification according to the WHO criteria 1999 [20].
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IGT, but ORs were not significantly different from 1. Body
weight, BMI, waist circumference, sagittal abdominal dia-
meter and other skinfold thickness measurements were not pre-
dictive in this group of subjects.
 
Discussion
 
The main novel finding of the present study is that subscapular
skinfold thickness was a predictor of the presence of persistent
IGT, independent of other variables including 2-h blood glu-
cose level at the initial OGTT, age, sex and family history of
diabetes, while other indices of obesity (i.e. BMI, waist) were
not, or only weak predictors of persistent IGT. Because sub-
scapular skinfold thickness is related to the subcutaneous fat
depot, these data suggest that subcutaneous adipose tissue
accumulation, especially in the truncal and central regions, is
linked to disturbances in glucose tolerance.
The population described in the present study is a subpopu-
lation from a larger lifestyle-intervention trial (SLIM). Subjects
do not necessary reflect the general population, as they were
 
Transient IGT Persistent IGT 
Variable (n = 40) (n = 47) P-value
Sex (M/F) 19/21 26/21
Age (years) 56.4 – 1.1 56.2 – 1.2 NS
Weight (kg) 81.6 – 2.4 83.8 – 1.7 NS
BMI (kg/m2) 28.4 – 0.6 29.4 – 0.6 NS
Waist (cm) 97.8 – 1.8 101 – 1.4 NS
WHR 0.94 – 0.01 0.97 – 0.01 0.07
Sagittal abd. dm (mm) 233 – 5.3 242 – 3.8 0.07
Transverse abd. dm (mm) 362 – 6 376 – 4.6 0.07
Biceps SKF (mm) 15.0 – 1.1 15.6 – 1.0 NS
Triceps SKF (mm) 19.4 – 1.6 19.3 – 1.3 NS
Peripheral SKF (mm) 34.4 – 2.6 34.9 – 2.2 NS
Subscapular SKF (mm) 25.4 – 1.4 29.8 – 1.2 0.02
Supra-iliacal SKF (mm) 29.7 – 1.5 31.3 – 1.1 NS
Truncal SKF (mm) 55.1 – 2.7 61.1 – 2.0 0.07
Sum of SKF (mm) 89.5 – 4.7 96.0 – 3.8 NS
HbA1c (%) 5.8 – 0.1 5.8 – 0.1 NS
Initial OGTT
Fasting glucose (mmol/l) 5.6 – 0.1 5.8 – 0.1 0.09
2-h glucose (mmol/l) 9.8 – 0.1 10.2 – 0.1 < 0.01
Data are expressed as mean – SEM. BMI, Body mass index; WHR, waist—hip ratio; abd. dm, 
abdominal diameter; SKF, skinfold thickness; NS, not significant.
Table 2 Clinical characteristics of subjects 
with transient and persistent impaired glucose 
tolerance (IGT)
 
(SD) OR 95% CI P-value
Weight (13.4 kg) 1.08 0.66—1.76 NS
BMI (3.8 kg/m2) 1.23 0.79—1.89 NS
Waist (10.3 cm) 1.34 0.82—2.21 NS
WHR (0.075) 1.73 0.90—3.29 0.09
Sagittal abd. dm (29.5 mm) 1.29 0.81—2.04 NS
Transverse abd. dm (34.8 mm) 1.52 0.89—2.58 NS
Biceps SKF (6.7 mm) 1.32 0.72—2.42 NS
Triceps SKF (9.3 mm) 1.28 0.58—2.83 NS
Peripheral SKF (15.3 mm) 1.35 0.65—2.80 NS
Subscapular SKF (8.5 mm) 1.84 1.06—3.19 0.03
Supra-iliacal SKF (8.4 mm) 1.12 0.70—1.79 NS
Truncal SKF (15.3 mm) 1.47 0.88—2.47 NS
Sum of SKF (27.7 mm) 1.47 0.83—2.61 NS
Odds ratios (OR) and 95% confidence interval (95% CI) for persistent impaired glucose 
tolerance, for a 1 SD difference in selected variables (adjusted for sex, age, family history 
of DM and 2-h glucose at initial test). BMI, Body mass index; WHR, waist—hip ratio; abd. 
dm, abdominal diameter; SKF, skinfold thickness; NS, not significant.
Table 3 Predictive value of selected 
anthropometric variables
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selected to participate in a 3-year lifestyle-intervention trial.
Furthermore, the size of the population was relatively small
(
 
n
 
 = 108). However, we do not believe these limitations affect
our main conclusions.
The OGTT is considered the gold standard in diagnosing
glucose intolerance. However, the reproducibility is rather
poor, because of the narrow range of the 2-h blood glucose
value used for defining IGT (7.8—11.1 mmol/l). Rates of
reversion to normal glucose tolerance of one-third to one-half
are reported for subjects with IGT [8,9]. This is in accordance
with the results of the present study. In total, 40 out of 108
subjects (37%) reverted to normal glucose tolerance at re-
testing (transient IGT); whereas 47 subjects (44%) remained
glucose intolerant (persistent IGT). This may reflect both
regression to the mean and a lesser degree of arousal or stress
at the second test.
We determined glucose tolerance during the first test in capi-
llary blood and during the second test in venous plasma. It is
known that glucose levels are higher in capillary blood com-
pared with venous blood or plasma. However, for classifica-
tion of the subjects we used, at both occasions, the appropriate
set of criteria according to the WHO, i.e. capillary criteria for
the first OGTT and venous plasma criteria for the second test
[20]. We validated this in a comparable population and
observed a good consistency in classification (69%, 
 
k
 
 0.55,
 
P
 
 < 0.001 [21]). These results indicate that the difference in
methods used for measuring blood glucose during OGTT do
not change the interpretation of our data.
Although transient IGT indicates a predisposition to dia-
betes [10], the incidence of diabetes is higher in subjects with
persistent IGT [11,22]. Factors predicting persistent glucose
intolerance include increased insulin levels, obesity, and posit-
ive family history of diabetes [13,14]. In the present study, sub-
scapular skinfold thickness was significantly associated with
an increased risk of persistent IGT, even after correction for
2-h blood glucose levels at the initial test, while measures of
(abdominal) obesity were not or only weakly associated with
an increased risk of having persistent IGT. These results sug-
gest that body fat distribution is more important than total
body fat mass in relation to transient or persistent glucose
intolerance. Although waist circumference is an important risk
factor for Type 2 DM [15], it only predicted weakly the pres-
ence of persistent IGT. However, our data were obtained in
a relatively small group of middle-aged people (
 
n
 
 = 108;
56.3 years) with an elevated BMI (29.2 kg/m
 
2
 
). It would be
interesting to evaluate the performance of measurement of
subscapular skinfold thickness and other anthropometric
measures in a larger sample.
Whether visceral or subcutaneous abdominal fat is most
strongly linked to insulin resistance is still unanswered [23].
Excess supply of free fatty acids (FFA) from visceral fat directly
via the portal vein to the liver can have several adverse effects
on hepatic metabolism, leading to hyperglycaemia and hyper-
insulinaemia [24]. However, although subcutaneous abdom-
inal adipose tissue may be metabolically less active, it is a
considerably larger fat mass than the visceral fat compartment
[25], resulting in a large release of FFA into the circulation.
Abate 
 
et al
 
. [25] concluded that subcutaneous truncal fat plays
a major role in obesity-related insulin resistance in men,
whereas intraperitoneal fat and retroperitoneal fat were less
important. In our study subscapular skinfold thickness, an
estimate of subcutaneous (central) fat, predicted the presence
of persistent glucose intolerance even after correction for
2-h blood glucose level during the first test. Measures of total
fat mass, as BMI, and others reflecting deep visceral fat
mass, were less predictive of persistent glucose intolerance.
This agrees with previous studies showing an association
between (subscapular) skinfold thickness and glucose tolerance
[17,18,26]. This suggests that the subcutaneous abdominal fat
depot influences disturbances in glucose homeostasis among
overweight subjects.
In summary, our results revealed that besides 2-h blood glu-
cose at the initial OGTT, subscapular skinfold thickness was
the best predictor of persistent IGT. In middle-aged men and
women, simple anthropometric measurements may improve
the discrimination between subjects with transient and persist-
ent IGT, enabling identification of those most at risk of Type
2 diabetes.
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